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This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer
metabolism, identify current obstacles to HP (hyperpolarized) 13C magnetic resonance imaging’s (MRI’s)2018 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.
is is an open access article under the CC BY-NC-ND license (http://
eativecommons.org/licenses/by-nc-nd/4.0/).
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2 Clinical Translation of Hyperpolarized Carbon-13 MRI Kurhanewicz et al. Neoplasia Vol. 21, No. 1, 2019widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH
white paper on hyperpolarized 13C MRI in 2011, preclinical studies involving [1-13C]pyruvate as well a number of
other 13C labeled metabolic substrates have demonstrated this technology's capacity to provide unique metabolic
information. A dose-ranging study of HP [1-13C]pyruvate in patients with prostate cancer established safety and
feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian
cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition
sequences and improved MRI hardware have been developed. It will be important to continue investigation and
development of existing and new probes in animal models. Improved polarization technology, efficient
radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the
technology in healthy control subjects and patient populations. It will be critical to determine how HP 13C MRI
might fill existing needs in current clinical research and practice, and complement existing metabolic imaging
modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important
factors in translating the technology for clinical research in oncology. This white paper is intended to provide
recommendations with this goal in mind.
Neoplasia (2019) 21, 1–16T
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ecent advances in cancer metabolism have generated considerable
terest among clinicians.1,2 However, the only imaging agent regularly
ed in the clinic to assess metabolism is the glucose analog [18F]
orodexoyglucose (FDG), a positron emission tomography (PET) tracer
at reports on local glucose uptake in many cancers, inflammation, and
her processes. While FDG PET has been an extremely successful
proach, it cannot assess downstreammetabolism that is often important
more fully understand cancer. Hyperpolarized magnetic resonance
aging (HPMRI) provides a unique window into metabolic alterations
sed on its ability to measure molecular transformations of the imaging
ent.3–6 Themethod dramatically, although temporarily, increasesMRI
gnal, which allows in vivo imaging of biologically active molecules that
as impossible with conventional methods. Dynamic nuclear polariza-
n of 13C-labeled biomolecules (probes) is currently the dominant
perpolarization process used for preclinical work, and it is the only one
at has been translated to patient studies. Due to space limitations, this
hite paper will focus on dynamic nuclear polarization–based
larization of 13C probes, although there are other methods to generate
P 13C-probes including para-hydrogen and brute force–based
proaches,5,7–9 and other nuclear magnetic resonance active nuclei
ch as 129Xe, 15N, and 31P have been hyperpolarized.10,11
The potential to diagnose and better characterize cancer biology,
edict cancer progression,12–17 and monitor early response to
eatment16,18–33 using HP MRI was highlighted in the first NIH
hite paper on this technology in 2011. Since then, a polarizer
pable of producing hyperpolarized material for human injection was
mmercially introduced, and the safety of hyperpolarized [1-13C]
ruvate as a tool for measuring changes in tumor metabolism in
tients was demonstrated.34 This white paper will highlight
eclinical advances, technical needs, and early experience with
tients and discuss how HP MRI might fill existing needs in
rrent clinical research and practice. Finally, we will examine
stacles to HP MRI's widespread clinical use and outline a path for
earing them.he Continuing Need for Animal Models
addition to providing the only plausiblemethod for testing the feasibility
d safety of new HP molecular probes, preclinical animal studies are
ucial for refining the methods for their use in specific diseases and for
lidating quantitative HP measurements of metabolism against tissue
says. Animal studies also provide the opportunity to better understand
ndamental aspects of biochemistry and its modification by disease,
erapy, nutritional state, and prescribed experimental conditions,
hich is possible in preclinical models but not in patients. Even if some
P probes prove inappropriate for clinical translation, their use in
eclinical studies can still yield information of real clinical value by
ucidating themetabolic pathways that novel treatment strategies could
rget.13,35,36 Studies in animal models are also critical to drive basic
ience discovery of new metabolic drug interventions, where further
plications of this technology might be beneficial in helping patients.
PPyruvate for Diagnosis, Progression, and Response to Therapy
[1-13C]pyruvate was among the first HP probes introduced and
mains the most widely studied in preclinical cancer models because
is easy to polarize, T1 is relatively long, and it occupies a critical
anch point central to a number of significant metabolic pathways.
yruvate is the product of glycolysis, and its major fates include
duction to [1-13C]lactate via the enzyme lactate dehydrogenase
DH) or oxidative metabolism to acetyl-coA with production of [13C]
carbonate in the mitochondria. Both processes result in an altered
emical shift that HPMRI is able to image at uniquely high temporal
solution. Although some exceptions have been observed,37,38 the
ajority of preclinical cancer studies using HP pyruvate as a biomarker
ve shown increased conversion to HP lactate, consistent with the
evated lactate production (Warburg effect) that is an established
aracteristic of most cancerous cells.12–17,39–42 These studies also
monstrated a mechanistic link between increased HP lactate signal
d other cancer-associated cellular alterations such as the elevated
pression of LDHA and monocarboxylate transporters, and lowered
in the extracellular environment. The accompanying reduction in
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Neoplasia Vol. 21, No. 1, 2019 Clinical Translation of Hyperpolarized Carbon-13 MRI Kurhanewicz et al. 3ruvate dehydrogenase activity can also be directly measured via
pearance of HP [13C]bicarbonate from [1-13C]pyruvate or HP
-13C]glutamate from [2-13C]pyruvate.19,20
Elevated transformation of hyperpolarized pyruvate to lactate has
en established as a predictor of tumor progression in the transgenic
enocarcinoma of the mouse prostate "model" and genetically
gineered pancreatic cancer models,43,44 while a similar effect was
so seen in longitudinal studies of liver cancer models,45 alongside
creased transamination of pyruvate to alanine. The latter effect
pears to be specific to the hepatic tumor phenotype and may be
agnostic of tumor type or stage. These applications demonstrate HP
RI's value as a tool for prognosis and treatment planning. In
dition, the ability to measure the metabolic information at a key
anch point involved in downstream glucose metabolism provides
formation that is unique and complementary to FDG PET. HP
-13C]pyruvate MRI provides insight into metabolism of a substrate
her than glucose, and the synergistic combination of the two
ethods may offer significant advantages in identifying and
aracterizing cancer. For example, it was recently demonstrated in
PET/MRI study where FDG-PET and HP MRI were simulta-
ously acquired (hyperPET) that FDG-PET cannot demonstrate the
arburg effect per se but does discriminate between glycolysis and
idative phosphorylation in contrast to HP MRI.46,47
HP MRI of pyruvate and its products is sensitive to the effects of
ticancer therapies including DNA-damaging agents, radiotherapy,
tivascular agents, targeted therapies, hormonal therapy, and
timetabolites—all of which have been reported to lead to a drop
HP lactate labeling, mediated by different mechanisms in the
rious treatments.9,11–25 Additionally, the metabolism of HP
marate to malate is sensitive to therapies that induce necrosis,
ch as VEGF neutralization and chemotherapy.31,33,48 Despite
me exceptions,38,48 in general, preclinical data suggest that
easurements from HP MRI of pyruvate predicts posttherapy cancer
ability and aggressiveness. It will be important to preclinically test
e hypothesis that therapeutic response can be determined at an
rlier stage than that at which reduced tumor size is observable using
atomic imaging modalities as is done in the Response Evaluation
riteria in Solid Tumors approach.49 Given the needs of a
rsonalized approach to treatment, HP MRI's capacity to expedite
sessment of response to therapy holds obvious value; this may be
pecially true in the case of early detection of nonresponse to therapy,
hich would enable more rapid adoption of alternate treatment
rategies.
xisting and Prospective Probes
Numerous molecules in addition to [1-13C]pyruvate have been
ccessfully polarized and used to study multiple biological processes,
cluding [2-13C]pyruvate, [1-13C]acetate, [1-13C]alanine, 13C
ea/[13C,15N2]urea, perdeuterated [U-
13C6]glucose, [
13C]bicar-
nate, [1,4-13C2]fumarate, and several others.
50,51 [1-13C]acetate
s been used to study tricarboxylic acid cycle flux and fatty acid
idation in heart and skeletal muscles through its conversion to
etyl-CoA by acetyl-CoA synthase,52,53 while HP butyrate has been
ilized to study ketone body metabolism and short-chain fatty acid
thways.54 HP alanine has been employed as an alternate probe to
udy metabolism in the muscle and liver.55,56 HP glucose has been
ed to monitor flux via the pentose phosphate pathway, as well as
ycolytic flux and lactate production57,58; [1-13C]dehydroxyascor-
te has been imaged and used to monitor intercellular redox statusd to inform on response to treatment by measuring the modulation
the tumor microenvironment59–61; HP [1-13C]alpha-ketogluta-
te has been used to track the neomorphic oncogenic activity of
utant IDH via its metabolism to the oncometabolite 2-
droxyglutarate and glutamate.62,63 More recently, HP [1-13C]
utamine has been used to directly measure metabolic flux to 2-
droxyglutarate, demonstrating a methodology to trace nutrient of
igin to a product in vivo.64 HP [2-13C]dihydroxyacetone has been
ed to assess hepatic gluconeogenesis,65 while HP acetoacetate has
en proposed as an indicator of mitochondrial redox status, although
utility has not yet been studied in tumors.66 The utility of inert
etabolic probes such as 13C-urea or 13C,15N2-urea has also been
own in simultaneous acquisitions with metabolized species as a
eans to normalize delivered agent concentration and uptake
netics, or as independent markers of perfusion in tumor tissue.67
his combined acquisition has the potential to alleviate technical
allenges in accurately determining metabolic and hemodynamic
anges associated with treatment response.68–70
Numerous biologically relevant, potentially polarizable molecules
main unstudied,71 and new HP probes to detect and assess response
various types of cancer treatment are urgently needed. For example,
cause MRI of HP pyruvate is unable to differentiate increased
ctate production associated with tumor cells from that associated with
flammatory cells, other probes—such as the recently tested HP
-13C]arginine—are necessary for monitoring response to therapies
at target this cell type.72 In addition, the development of
perpolarized biomarkers capable of monitoring response to the
ost promising immunotherapies currently in use, such as checkpoint
hibitors, is a major unmet need which should command immediate
eclinical attention. Probes tailored to the innate or designedmetabolic
aracteristics of such cellular therapeutic agents would be extremely
luable for assessing treatment efficacy at a very early stage.
urther Avenues of Preclinical Animal Study
Preclinical animal studies enable investigation of appropriate
ethods to report HP data or integrate multiple HP measurements,
r example, through the development and testing of methods for the
ue simultaneous measurement of perfusion and metabolism to
prove quantitation69 and facilitate identification of poorly perfused
t metabolically active disease that is often highly aggressive and
fficult to treat.73 The possibility of acquiring such a combined
easurement was demonstrated using copolarized [1-13C]pyruvate and
C urea in rats: metabolic alterations were registered via the conversion
pyruvate into 13C bicarbonate, while alterations in perfusion were
easured via changes in myocardial signals of pyruvate and urea.60 The
velopment of HP probes and pulse sequences capable of simulta-
ously measuring perfusion/metabolism mismatch in cancerous tissue
s the potential to provide valuable information regarding tumor
terogeneity, with obvious implications for the development of more
nsitive and personal treatment.73 Similar possibilities exist for additional
tiometric measurements (e.g., local pH derived from CO2:HCO3
tio,74–78 or redox state in different intracellular compartments derived
om lactate:pyruvate ratio,37,79,80 α-ketoisocaproate:leucine ratio,81,82
ascorbate:dehydroascorbate ratio).59,60 These combinations are being
plored or developed in animal, organ, and cell research models with the
tential for future clinical application. The unique ability to image
ultiple metabolites simultaneously—either through the injection of a
gle hyperpolarized agent that is variously metabolized or via the
jection of several HP agents at once—means that HPMRI technology
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4 Clinical Translation of Hyperpolarized Carbon-13 MRI Kurhanewicz et al. Neoplasia Vol. 21, No. 1, 2019particularly suited to this kind of combined measurement. Because
tiometric measurements are potentially subject to bias in the case of
ffering uptake or relaxation characteristics, preclinical models are critical
r validation using histological and invasive techniques that are not
actical in human subjects.
In addition to exploring HP technology, preclinical animal studies
able measurements that are not feasible in human subjects for
asons such as invasiveness, toxicity, or the current inability to
perpolarize substrates in sufficient volume. Studies using geneti-
lly engineered and patient-derived xenograft models enable the
mbined use of PET and HP MRI, as well as the collection of a
bust spectrum of supporting in vivo and histological measurements,
cluding metabolite and enzyme profiles as well as histochemical
easurements of enzyme heterogeneity, which can both confirm and
hance the data collected via these primary imaging modalities.
hile the ability to collect such supplementary measurements is
doubtedly crucial to validating the accuracy of primary measure-
ents enabled by HP probes, its ultimate value may lie in the more
neral expansion of our understanding of the biochemical properties
aracteristic of specific disorders. For example, HP probes are
rrently being used to assess the progression of lung83 and brain84
jury, yielding valuable insights into the mechanism of injury
opagation. While these studies are not directly applicable to
aging human injury using HP agents in the clinic, the information
ined will help guide therapeutic approaches that could have
gnificant clinical impact.
eeds and Future Directions
There is substantial need for preclinical polarizers capable of
hieving high polarization and tailored for producing masses of
aterial suitable for rodent exams. Such a polarizer that is less
pensive than a clinical device would dramatically expand preclinical
forts and speed clinical investigations. High levels of polarization
crease the signal-to-noise ratio and potentially open up previously
detectable biological pathways for study. High levels of polarization
ay also allow a reduction in the injected probe concentration. HP
obes are injected at physiologic or supraphysiologic doses, and
eclinical studies investigating the extent to which physiologic
ncentrations of HP probe might perturb in vivo metabolism
lative to a tracer approach like PET are key to the proper
terpretation of HP MRI findings. As previous work has
monstrated, this increased polarization is most easily achieved by
ploying higher magnetic fields and lower temperatures during the
larization process.85,86
Optimized pulse sequences can also be used to preserve the
agnetization of specific hyperpolarized substrates while enhancing
e detection of products.4,87 Since the lack of standardized
chniques remains an obstacle to the growth of HP MRI as a field
study, this represents a potential opportunity for the research
mmunity to collaborate with small imaging system manufacturers
the creation of standard imaging sequences and basic processing
otocols, thereby possibly expanding the use of HP MRI techniques
yond labs with a strong MRI physics focus. Other beneficial
chnical improvements would include the development of a less
mplex user interface, as well as a more direct, rapid mechanism for
e delivery of polarized agents into the animal or cell or tissue culture
oreactor.
The development and optimization of new hyperpolarized
olecular probes, and preclinical studies that accurately recapitulateportant aspects of human disorders—whether using primary cells
d tissues, genetically engineered, patient-derived xenograft, or other
odels—continue to be of great value. Robust mechanistic validation
king hyperpolarized metabolic observations to established biolog-
al events are also essential to establish the value of hyperpolarized
aging approaches and their potential limitations. Significant effort
currently under way—and should be further encouraged—to
plore the use of HP imaging biomarkers to inform on a variety of
sease conditions and therapeutic strategies and to integrate this
ique new information to positively affect outcome. The combined
e of targeted therapeutic approaches and HP MRI in these models
ill provide a framework for accessing HP biomarkers of treatment
sponse for clinical translation. It is also important to conduct more
udies to validate the use of HP MRI in combination with other
aging modalities such as PET, as was recently done during a single
aging session in a canine cancer model.46,47 The value of
mbining these measurements lies not only in a more complete
aracterization of the cancerous tissue being imaged but in reduced
an time and more efficient use of resources.ecessary Technical and Analytic Developments
ccess with preclinical studies encouraged a more translational focus.
order to enable clinical trials, several specific technical develop-
ents were necessary. In the following section, we will outline some
the recent technical progress and note additional opportunities.
Device for Polarization
Over the past 10 years, there have been significant improvements
polarizer hardware, from initial prototypes suitable for rodent
ams to current commercial products that can support human
udies.88 The performance in terms of polarization and speed of
livery has been adequate for initial [1-13C]pyruvate studies, but
rther developments are needed to achieve higher and faster
larizations reliably with increased cost-effectiveness, and to
reamline methods of HP probe sterile delivery for pyruvate and
her HP probes for future clinical research. Next-generation
larizers that are optimized for preclinical research will also be
tal for supporting the development of new hyperpolarized agents
d their use in basic science and translational research.
aging Hardware
Another important commercial goal should be improved 13C MR
aging hardware. While each major MR scanner vendor offers
oduct hardware enabling the excitation and detection of hyperpo-
rized signals at the 13C frequency, several additional modifications
ould significantly improve the performance and applicability of this
chnology. Commercially available double-tuned body coils would
eatly benefit human studies by allowing uniform excitation for 13C
er any target disease site, as is the case for conventional 1H MRI.
urrent studies have been limited by both the 13C detector hardware
d short acquisition times due to metabolism, signal relaxation, and
citation losses; thereby necessitating the use of strategies that more
ficiently encode magnetization.69,89,90 As in 1H MRI, detector
rays with a high number of elements can facilitate higher
celeration rates to generate images faster and with increased spatial
verage and resolution. For optimal clinical studies, scanners with a
eater number of receive channels (at least 32 channels) are needed to
pport 13C detector arrays with geometries that are optimized for all
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Figure 1. Schematic showing the required components for HP 13C MRI clinical translation. Thirty-two-channel head coil.
Neoplasia Vol. 21, No. 1, 2019 Clinical Translation of Hyperpolarized Carbon-13 MRI Kurhanewicz et al. 5dy regions. Dual-tuned or nested receive arrays that would permit
gh-quality “standard of care” 1H MRI alongside sensitive 13C
tection without repositioning or replacing coils in order to enhance
tient comfort and workflow. Higher-performance gradients will
so be critical for improving the speed, coverage, and performance of
P 13C MRI, which requires four times higher gradient strengths to
hieve the same effect as for 1H MRI. The progress seen in highly
rallel acquisition of 1HMRI over the past few years provides reason
believe that these radiofrequency (RF) coil challenges can be met
ithin the constraints imposed by currently available gradient bores.
he increased costs would be a very small fraction of total system cost
d easily justified by the greatly enhanced capabilities. The
velopment of appropriate phantoms that enable testing of new
chniques for HP 13C MRI prior to human studies is also important
r advancing the field. Static phantoms containing 13C-enriched
mpounds facilitate technical development and quality assurance
sting to confirm scanner and coil performance at thermal
uilibrium, while dynamic phantoms that simulate the kinetics of
emical conversion in vivo91 are important to develop and validate
antitative dynamic imaging measurements.
cquisition Methods for Human Studies
The high signal-to-noise ratio provided by this hyperpolarization
chnique makes high-resolution acquisitions feasible. However,
pid metabolism and short T1 relaxation times can limit the matrix
ze—and thus the spatial resolution and coverage possible—with
nventional phase-encoding. The MR acquisition techniques used
r initial animal studies and the first human trial34 were limited in
atial coverage (typically b8 cm) and dynamic temporal information.
his clinical trial used single-slice dynamic 13C echo-planarectroscopic imaging (EPSI) in some patients to estimate the correct
arting time for a 12-second 3D EPSI single time-point acquisition
subsequent patients with a small FOV of 8-10 cm.34 Dynamic 1D
PSI measurements efficiently encode frequency and space along the
adout direction following a single excitation. Extension to multiple
atial dimensions requires additional excitations and phase encoding
petitions for each dynamic time point. New acquisition and analysis
chniques are needed for volumetric, dynamic HP MR data with
proved spatial coverage and temporal resolution. Most preclinical
d clinical research studies have used spectroscopic-based acquisi-
ns, but imaging-based acquisitions including balanced steady-state
ee precession sequences,92,93 spectral-selective echo-planar,94 and
iral trajectories68,95–97 have clear advantages in terms of speed and
se of implementation and analysis. Methods combining 13C and
excitation and reception could benefit the detection of many
etabolites via decoupling and indirect detection.98,99
econstruction, Dynamic Modeling, and Enzyme Rate Con-
ants
Ideal dynamic MRSI data would be resolved in three spatial
mensions, the spectral dimension, and time with adequate coverage
d speed to enable reliable quantification of metabolic parameters.
rtunately, the spectrum is sparse, with only a few spectral lines. In
dition, the time dimension is slowly varying. These two features
low the amount of encoding required to be greatly reduced by using
mpressed sensing reconstructions along with low-rank or model-
sed reconstruction in the temporal dimension.89,100,101 Spatial data
duction strategies, including parallel and constrained imaging
ethods, are crucial for reducing the number of excitations that are
cessary to reconstruct dynamically changing data.102 Fewer
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Figure 2. Images are from a representative patient with a current PSA of 3.6 ng/ml, who had biopsy-proven prostate cancer in the left apex
(Gleason grade 3 + 4) and received the highest dose of hyperpolarized [1-13C]pyruvate (0.43 ml/kg). (A) A focus of mild hypointensity can
be seen on the T2-weighted image, which was consistent with the biopsy findings. (B to D) 2D localized dynamic hyperpolarized [1-
13C]
pyruvate and [1-13C]lactate from spectral data that were acquired every 5 seconds from voxels overlapping the contralateral region of
prostate (turquoise), a region of prostate cancer (yellow), and a vessel outside the prostate (green). The dynamic data were fit to provide
kPL as described previously.
139 Figure taken from Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PEZ, Harzstark AL, Ferrone M, et al.
Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate. Science Translational Medicine
2013;5:198ra108-198ra108.
6 Clinical Translation of Hyperpolarized Carbon-13 MRI Kurhanewicz et al. Neoplasia Vol. 21, No. 1, 2019citation pulses preserve HP magnetization, allowing for increased
verage, higher excitation angles, or prolonged interaction with
rget biology. Optimized excitation schemes are required to permit
rther sensitivity enhancement.
Parallel imaging reconstructions can be challenging since signal at
ermal equilibrium is too weak for practical measurement of sensitivity
aps. Autocalibrating methods such as GRAPPA (GeneRalized
utocalibrating Partial Parallel Acquisition) can avoid wasting
larization and imaging time acquiring sensitivity maps but can be
oblematic because the fully sampled central region can be a large
action of the sampled k-space volume which limits acceleration. Care
ust also be taken to ensure that undersampled parallel imaging data are
quired in such a way that the data are self-consistent enough to satisfy
ndamental assumptions about the relationship between under-
mpled data. Alternatively, undersampled k-space data can be usedcompute the coil sensitivities as with a calibration-less approach for
P 13C MR.103 Further investigations are needed to develop
quisition strategies that minimize uncertainty while maximizing the
ficiency of spatial, temporal, and spectral encoding—including
ethods that exploit redundant information that could be derived
om conventional 1H MRI.
MRI of hyperpolarized substrates is unique among diagnostic
aging modalities in its ability to provide information about
namic chemical interactions and imaging agent metabolism. New
proaches for characterizing the transient interaction between the
aging agent and targeted biological processes are therefore required.
variety of approaches have been proposed, including semiquanti-
tive area under the curve measurements—such as the normalized
ctate ratio— that reflect the ratio of locally observed product to
ecursor and product, “snapshot” measurements of metabolite
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Figure 3. Representative axial T2-weighted anatomic image and corresponding water apparent diffusion coefficient (ADC) image and T2W
image with an overlaid pyruvate-to-lactate metabolic flux (kPL) image and corresponding HP
13C spectral array for a 52-year-old prostate
cancer patient with extensive high-grade prostate cancer (A) before therapy and (B) 6 weeks after initiation of androgen ablation and
chemotherapy. Before treatment, the region of prostate cancer can be clearly seen (red arrows) as a reduction in signal on the T2W and
ADC images, and increased HP lactate and associated kPL on. Pretreatment, HP [1-
13C]pyruvate CS-EPSI demonstrated a large region of
high HP Lac/Pyr ratio, resulting in a high kPL, which is consistent with region of decreased T2 MRI signal and water ADC associated with
biopsy-proven Gleason 4 + 5 prostate cancer. At 6 weeks after initiation of androgen deprivation therapy, repeat HP 13C MRI
demonstrated nearly complete abrogation of elevated HP lactate peaks and associated near-complete diminution of intratumoral kPL
values on dynamic imaging (kPL max 0.025 s
−1 at baseline and 0.007 s−1 on follow-up). Notably, there were negligible change in size of
tumor on T2-weighted MRI and only a modest change on ADC imaging, supporting the ability of HP
13C MRI to detect early metabolic
responses before such a response can be ascertained using standard radiographic criteria. Concordant with these findings, the patient
subsequently achieved a marked clinical response, with an undetectable serum PSA nadir at 6 months after ADT initiation. Figure taken
from Aggarwal, R., Vigneron, D.B., and Kurhanewicz, J. Hyperpolarized [1-13C] Pyruvate Magnetic Resonance Imaging Detects an Early
Metabolic Response to Androgen Ablation Therapy in Prostate Cancer, Eur Uro, July 23, 2017;72(6)1028-1029. PMCID:5723206.
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netic analysis of dynamic multispectral data has shown the ability
both preclinical and human studies (Figure 1) to derive rate constants
r substrate conversions such as kPL, the spectroscopic/imaging
omarker for the calculated rate at which HP pyruvate is converted
to lactate.18,34,69,104,105 Quantitative measures such as kPL can
ovide important quantitative parameters for many applications where
ecise measurements are needed to quantify changes in specific drivers
aerobic glycolysis. Recent literature shows the strong correlation
tween perfusion and metabolic measures of kPL
69,94 with cancer
gressiveness and response to therapy. To realize the inherent promise
the unprecedented new information afforded by HP substrates,
rther research is critically needed to develop and test new accurate,
producible quantitative analysis methods.
Once achieved, the technical and analytical developments outlined
ove should help to significantly accelerate the translation of HP 13C
RI to the clinic and increase its biomedical value—both by
abling studies which offer further proof of the improved molecular
aging capabilities it has already displayed and by optimizing their
tential clinical utility.
ranslation to Patients with Cancer
he first-in-human study convincingly demonstrated that injection
HP [1-13C]pyruvate is safe and that imaging metabolic products ofperpolarized [1-13C]pyruvate metabolism is feasible 34. Since then,
number of significant technical improvements relevant to improving
ta quality and preserving safety have been implemented. These
clude improved technology and strategies for generating sterile
perpolarized material using a commercial device, the SPINlab, new
R data acquisition sequences, and multichannel 1H/13C radio
equency RF coils. Pictured in Figure 2 is the workflow for the
rrent-generation SPINlab which is now used routinely in patient
udies and provides automated polarization, dissolution, and quality
surance system. The SPINlab polarizer uses a 5-T magnetic field
d operates at ~0.8 K. It has the capacity to polarize up to four
mples simultaneously, thus opening the door for the injection of
ultiple HP probes within a single imaging exam. A critical part of
e SPINlab polarization and quality assurance process is the fluid
th that enables polarization in a closed system to minimize the
tential for microbial contamination. Compared to the initial
man study using a prototype polarizer in a clean room, the
hievable polarization of [1-13C]pyruvate has more than doubled
rom ≈18% to ≈40%), and the time to delivery of HP 13C pyruvate
as reduced (from ≈68 seconds to ≈55 seconds). Around the world,
ven sites have performed human exams using the SPINlab polarizer,
d more than 20 have been installed.
While initial patient studies have focused on [1-13C]pyruvate,
-13C]pyruvate has recently been FDA approved and is being added
to
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Table 1. Current Hyperpolarized 13C MRI Clinical Trials—ClinicalTrials.gov
Hyperpolarised 13C-Pyruvate MRI Study Cancer
Cardiovascular diseases
University College London, London, UK
Effect of Cardiotoxic Anticancer Chemotherapy on the
Metabolism of [1-13C]Pyruvate in Cardiac Mitochondria
Breast neoplasms UT Southwestern–Advanced Imaging
Research Center, Dallas, TX, USA
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic
Imaging in Predicting Treatment Response in Participants With Prostate Cancer
Prostate adenocarcinoma
PSA level greater than 10
Stage IIB prostate cancer AJCC v8
(and 7 more...)
M D Anderson Cancer Center, Houston,
TX, USA
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance
Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With
Central Nervous System Tumors
Malignant central nervous system neoplasm
Metastatic malignant neoplasm in the central nervous system
Stanford University School of Medicine
Palo Alto, CA, USA
Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13
Pyruvate
Traumatic brain injury UT Southwestern–Advanced Imaging
Research Center
Dallas, TX, USA
Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway Fatty liver
Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial
Metastasis Treated With (SRS)
Brain metastases Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical
Cancer (LACC) Cervical Cancer
Uterine cervical neoplasms Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Study to Evaluate the Feasibility of 13-C Pyruvate Imaging in Breast Cancer Patients
Receiving Neoadjuvant Chemotherapy
Breast cancer Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic
Resonance Spectroscopic Imaging (MRSI)
Brain tumor adult
UTSW HP [13-C] Pyruvate Injection in HCM Cardiomyopathy, hypertrophic UT Southwestern Medical Center - Advanced
Imaging Research Center
Dallas, TX, USA
Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in
Children With Brain Tumors
Pediatric brain tumors UCSF Helen Diller Family Comprehensive
Cancer Center, San Francisco, CA, USA
Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor
Malignancies
Prostate cancer University of California, San Francisco
San Francisco, CA, USA
Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in
Castration-Resistant Prostate Cancer
Prostate cancer University of California, San Francisco
San Francisco, CA, USA
Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer Prostate cancer Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection Hypertension
Hypertrophy
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Multiparametric MRI for Prostate Cancer Localization and Characterization Using
Hyperpolarized Pyruvate (13C) Injection
Prostatic neoplasms Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
A Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate
Cancer
Prostate cancer University of California, San Francisco
San Francisco, CA, USA
MRI With C13 Pilot Study Prostate Cancer Prostate cancer University of California, San Francisco
San Francisco, CA, USA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility Malignant solid tumors Memorial Sloan Kettering Cancer Center
New York, NY, USA
Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer Prostate cancer University of California San Francisco
8 Clinical Translation of Hyperpolarized Carbon-13 MRI Kurhanewicz et al. Neoplasia Vol. 21, No. 1, 2019[1-13C]pyruvate in ongoing clinical trials. Additionally, funded
inical research studies are working toward the use of 13C urea,
-13C]glutamine, [1-13C]alpha-ketoglutarate, and [1,4-13C2]fuma-
te in patient studies. To aid with submitting investigator-initiated
vestigational New Drug (IND) applications for future patient
udies, the IND for the use of [1-13C]pyruvate was transferred to the
CI and is available on the following website (https://imaging.cancer.
v/programs_resources/cancer-tracer-synthesis-resources/
perpolarized-C13-pyruvate-documentation.htm).
arly Patient Validation Studies
Early patient validation studies involving test-retest reproducibility,
rrelations with pathologic findings, and clinical outcomes such as
rvival and disease progression after treatment have been initiated
ata available from clinicaltrials.gov). In a study utilizing 2D
ynamic EPSI of preprostatectomy prostate cancer patients
CT02421380), time to max pyruvate was reproducible when
rrected for the arterial input function with no significant difference
served in repeat injections of the same patient within the same
am.106 In two recent clinical trials of prostate cancer patients
eprostatectomy (NCT02526360) and before and after treatment
CT02911467), a 3D dynamic compressed sensing EPSI sequenceas used to obtain full prostate coverage and to model the apparent
te of pyruvate to lactate conversion, kPL. In the setting of advanced
ostate cancer, early (6 weeks) after effective androgen deprivation
erapy, there was a significant early reduction in kPL that receded
anges in mp-1HMRI and predicted clinical response (Figure 3).107
omparison with current state-of-the-art imaging modalities such as
MRI is key to determining the added value of HP 13C MRI, and
ith current HP 13C MRI studies expanding to metastatic sites
ithin the body,108,109 the synergy of HP MRI with currently used
ET probes will also need to be investigated.
There are currently a number of single-institution HP 13C MRI
inical trials in the setting of breast, cervical, liver, and brain cancer,
d an initial multisite clinical trial for prostate cancer (Table 1).
ollowing promising preclinical studies in brain tumors, multiple
lerosis, and traumatic brain injury, the feasibility of using HP 13C
RI for evaluating brain metabolism in patient studies was recently
monstrated.110,111 These studies demonstrated that [1-13C]
ruvate are transported across the blood brain barrier and that
nversion to [1-13C]lactate can be detected in regions of both tumor
d normal brain. Interestingly, the rate of conversion in normal
ain was substantially higher than had previously been observed in
esthetized preclinical models. For dynamic slab-localized and 2-D
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Neoplasia Vol. 21, No. 1, 2019 Clinical Translation of Hyperpolarized Carbon-13 MRI Kurhanewicz et al. 9ho planar spectroscopic imaging data with 4-8 ml spatial resolution,
was also possible to observe the conversion of HP pyruvate to
carbonate, which may discriminate between tumor and normal
ain. Additional studies are needed to optimize the pulse sequences,
F coils, and experimental design to observe all three resonances at a
er resolution and with volumetric coverage. Single-institution
udies that have been funded by the NIH include protocols for
taining data from the normal brain, in primary brain tumors prior
image-guided surgery, and for comparing that conversion to
-13C]lactate/[1-13C]pyruvate in patients pre- and posttreatment
ith radiation and temozolomide.
There are also several clinical trials investigating noncancerous
seases, such as cardiomyopathy, hypertrophy and hypertension, and
tty liver disease (Table 1). Altered cardiac energetics is known to play
important role in the progression toward heart failure, and a recent
udy demonstrated the feasibility of assessing pyruvate metabolism in
vo in humans.97 The appearance of 13C-bicarbonate signal after
ministration of hyperpolarized [1-13C]pyruvate was readily detected
a cohort of healthy controls, suggesting that this technology may 1
y allow a direct measure of flux through the PDC in the in vivo
man myocardium, providing a means for understanding therapeutic
proaches that target metabolism.
While prior and ongoing HP 13C MRI patient studies have
dressed many of the initial obstacles, there remain a number of
allenges to the robust clinical translation of hyperpolarized [1-13C]
ruvate MRI and its full FDA approval, as well as the translation of
her new hyperpolarized probes into the clinic. These challenges are
scussed in the following section.H
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fuhallenges in Translation to Clinical Research and
ractice
ompared to current metabolic imaging methods based on positron
mography, HP 13C MRI technology offers superior information
eld about fluxes in metabolic pathways without the constraints of
nizing radiation. Nevertheless, while other potential benefits such as
fety and patient acceptability may be substantial, the central
estion for clinical translation is whether HP 13C MRI provides
tionable clinical information that is inaccessible by other methods.
examining how this question can be answered in the affirmative,
e can take some cues from the use of FDG PET/CT.112,113
he Clinical Role of Imaging in Cancer
The traditional clinical roles for imaging in cancer are detection,
agnosis, staging, and monitoring therapy.114 More specifically,
aging techniques are typically used in the clinic to detect the
mor through screening; to guide cancer diagnosis, including tissue
mpling; and to determine the extent of cancer spread. More recently,
olecular imaging in particular has been used as a cancer biomarker to
lp direct treatment.115,116 Already demonstrated in animal models20
d initial patient studies,107 this capacity to rapidly detect response to
eatment is perhaps the most promising in terms of clinical translation.
ecause a response to therapy prior to any change in tumor volume
uld occur within days, or even hours, the ability to detect this change
uld redirect therapy to improve therapeutic efficacy and avoid
necessary toxicity for ineffective treatments, potentially saving lives
d alleviating suffering.
The complexity, expense, and requirement for administering an
aging agent will likely limit HP MRI's role as a primary screening
ol. However, coupled to blood or urine metabolic biomarkersdicative of cancer risk and specific cancer metabolic signatures,117
P MRI could provide a very powerful, targeted detection tool in
ratified populations. It could play a key role in diagnosis, for
ample, as metabolic features identified by HP MRI might provide a
th sensitive and specific means of identifying cancer and clarifying the
nign ormalignant nature of findings seen on anatomic imaging—as is
e case in the application of FDG PET to pulmonary nodules detected
CT.118 Since HP MRI is readily coupled to the anatomic
formation acquired from standard MRI, it may also be particularly
lpful in directing tissue sampling by identifying the sites most
spicious for cancer or, in the case of large cancer or widespread lesions,
dicating the lesions that appear most aggressive. Finally, HP MRI
uld play a role in stratifying tumors identified by other imaging
odalities. Also, the application of HP MRI for systemic staging is
likely in the short term as it would require a whole-body capability
ilar to that of PET/CT, the development of which would have to
ercome several technical challenges. However, as discussed above,
ese technical challenges are beginning to be addressed in ongoing
ase II clinical trials of metastatic cancer.
Our understanding of cancer metabolism is primarily based on cell
d murine models whose relevance to human malignancies is
clear. Consequently, in addition to the traditional roles of
aging in cancer management, HP MRI could provide clinical
lue based on its capacity to identify specific therapeutic targets in
vo in humans, i.e., serve as companion diagnostics. Accordingly,
e presence of accelerated lactate production could direct the use of
H inhibitors, while altered mitochondrial metabolism might
ggest therapeutic options to renormalize metabolic activity.
ow Could HP Information Change a Therapeutic Decision?
Since the publication of the first white paper,3 a number of reports
ve appeared on the evaluation of cancer biomarkers and cancer
aging methods.114,117,119–122 HP 13C MRI holds great promise as
imaging biomarker of cancer. An imaging biomarker has been
fined as an anatomic, biochemical, or molecular parameter
tectable with an imaging method that is useful for establishing
e presence or severity of disease.123,124 As we have already
entioned, metabolic alteration is an important phenotypic feature
cancer that predicts disease behavior and can itself be a therapeutic
rget.121,125 A critical consideration in the translation of a new
omarker into the clinic is the impact of the test necessary for
taining this biomarker on clinical practice and patient outcome.119
other words, does the test lead to better, more effective, and/or
ore cost-effective patient treatment? As a cancer molecular imaging
omarker, HP 13C MRI has the potential to address the following
e clinical needs.115
First, HP MRI could prove beneficial by detecting disease prior to
initial clinical manifestation—in high-risk patients, for example—
as a secondary diagnostic test, indicating the likelihood that
normal findings from screening or staging studies represent a
alignancy. It could also prove valuable by helping to stratify disease
verity after a diagnosis. Second, HP MRI could identify specific
tes for tissue biopsy for cancer diagnosis and characterization. A
ird important benefit would be the capacity to predict disease
ogression based on evidence of metabolic hyperactivity or the
tegrity of metabolic pathways that enable metastasis. Fourth, HP
RI may provide an early, pharmacodynamic measure of drug
ficacy, which could in turn predict the likelihood of therapeutic
tility, by measuring the impact of a given drug on regional cancer
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10 Clinical Translation of Hyperpolarized Carbon-13 MRI Kurhanewicz et al. Neoplasia Vol. 21, No. 1, 2019etabolism. If validated, this would be a significant clinical
ntribution, as it would enable the avoidance of ineffective
emotherapy with the attendant morbidity and expense. Finally,
P MRI could prove useful in evaluating prognosis and indicating
erall response—using the eradication of aberrant metabolism as a
ghly predictive indicator of disease resolution, akin to the use of
DG PET/CT in lymphoma.126 In this context, the role of HP
ould be to determine whether or not treatment has eliminated the
ncer, as well as to help determine if there is a need for additional
eatment by predicting the likelihood of disease relapse or
ogression. In summary, biomarker applications are likely to
present the most compelling use of HP 13C MRI in relation to
ncer since its unique ability to characterize and quantify cancer
etabolism provides a means for inferring the impact of targeted
erapeutic interventions.122,127
hat Will a Clinician Look for in Studies of HP Validation?
Experience with cancer diagnostics119,120 suggests that the general
rm “validation”may refer to distinct criteria: validity with respect to
alytical results, validity for the purpose of a clinical diagnosis, and
lidity for the purpose of modifying patient care, which could also be
rmed clinical utility. In order to support the use of HP 13C MRI in
inical trials and clinical practice, investigations relevant to all three
asses of data will be needed.
Analytic validity will be an important question, as clinicians will
ed to understand what HP 13C MRI is measuring and see evidence
at these measurements are accurate. One approach to establishing
e analytic validity of HP MRI is to compare its results with those of
her PET-based tracer experiments. Demonstrating the reproduc-
ility of hyperpolarized imaging exams is another important step and
ill require establishing standardized and repeatable methods for HP
R image acquisition and interpretation. Clinical validity, on the
her hand, refers to the capacity of a test to separate a given patient
pulation into two groups, such as those with and without a disease.
o establish their clinical validity, HP MRI results must be compared
an accepted clinical standard such as the tissue or laboratory-based
says with which oncologists are most comfortable. Another
portant aspect of demonstrating HP MRI's clinical validity will
its comparison to FDG and other PET imaging methods, and for
is reason, investment in facilities capable of performing both exams
critical.
It is important to acknowledge, however, that establishing the
inical validity of a given technology does not in and of itself
monstrate that this technology should be used in patient care
cisions. Rather, that determination is ultimately based on clinical
ility, which refers to the technology's capacity to appropriately
rect patient care. In assessing the clinical utility of HP 13C MRI,
inicians will look for validation against clinical outcomes, accuracy
ensitivity, specificity, receiver operating characteristic area) versus a
ference standard in diagnostic applications, and predictive accuracy
assessing therapeutic response. It will therefore be important to
ow to what extent the data provided by HP MRI accurately
classify a patient, after all conventional studies are complete, into
e proper category—classified either as normal (with a normal HP
am) or as disease (with an abnormal HP exam). Additional criteria
ill include the risk or discomfort of the exam relative to the new
formation it provides and, of course, the cost. Utility will be a key
mponent of later clinical trials, in which assessment of the impact
patient outcomes and the cost of medical care provide data forverage decisions by payers, which is one of the most important
terminants of whether or not a new test is actually used in the
inic.119
omparison to Positron Tomography
Lessons learned from other quantitative molecular methods such as
ET can help guide the approach to quantitative image analysis using
P MRI. For example, studies have shown that more sophisticated
antitative methods such as compartmental kinetic analysis can
prove the ability to measure therapeutic response and predict
tient outcomes128; however, this improvement must be balanced
ainst the ability to implement more complex methods in the
inic.129 Experience suggests that necessary simplification is best
hieved by collecting detailed data in early studies and then testing
e impact of simplification against more rigorous analytic
proaches.130
Combining HP MRI and PET data in kinetic analysis may be
pecially powerful in characterizing cancer metabolism, as the two
ethods provide complementary information. Long half-life and
latively straightforward image quantification make PET a robust
ethod for quantifying flux through certain specific biochemical
thways, such as the flux of glucose through hexokinases as a
easure of glycolysis or of thymidine through TK as a measure of
llular proliferation. However, since isotopic emissions are not
pacted by the chemical species to which the isotope is attached,
ET provides no information about the nature of the molecule
tached to the label. HP 13C MRI, on the other hand, provides
quisite information on the evaluation of metabolites of the
jected substance—such as for lactate from pyruvate—while its
orter half-life makes studies of metabolic trapping difficult. Taken
gether, the two methods can provide comprehensive information
metabolic fluxes, especially at major branch points in metabolic
thways such as the conversation of pyruvate to lactate in
ycolysis.
uture Directions: Initial Studies and Clinical Study Design
Early Clinical Trials. Existing guidelines for designing and
porting on clinical trials of biomarkers provide a helpful template
r HP 13C MRI.131 Early studies must refine and test robust
ethods for image acquisition and analysis to provide a uniform (and
iformly accepted) approach to be used in subsequent clinical trials.
arly studies should also include tests of repeatability/precision to
easure the qualitative and quantitative variability of HP imaging
sults, typically using a test/retest paradigm.113 Guidelines based on
sults from early clinical trials are important for subsequent trials and
entual clinical use, as the NCI consensus guidelines on FDG PET/
T have demonstrated.132 Finally, early clinical trials should validate
P 13C MRI against an accepted reference standard for cancer
agnosis and characterization, typically based on tissue sampling.
his reference standard can be the presence or absence of cancer for
agnostic applications, or specific assays that might serve as a
ference for imaging measures and which are often established in
eclinical studies. In addition to standardizing imaging approaches,
porting of adverse events also could be standardized to facilitate
gulatory approval down the road.
The latter phase of imaging trials for biomarker applications should
aluate new imaging tests for their accuracy in predicting important
inical cancer outcomes such as therapeutic response, progression-
ee survival, and overall survival. Early studies must establish the
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Neoplasia Vol. 21, No. 1, 2019 Clinical Translation of Hyperpolarized Carbon-13 MRI Kurhanewicz et al. 11lue in clinical trials of HP 13C MRI as integrated markers, where
vel imaging is embedded in a clinical trial but is collected in a
rely observational fashion for comparison against clinical outcomes
easured in the treatment trial.133 Once validated in integral
omarker trials, the imaging marker can be used to direct therapy in a
inical trial and, later, in clinical practice. An example can again be
und in the application of FDG PET/CT to lymphoma, where the
solution of abnormal FDG uptake, known as a complete metabolic
sponse, was shown to be highly predictive of disease-free survival
d is now used as an integral marker in clinical trials and for clinical
actice.126
Multisite Trials. Multisite clinical trials will be expected prior to
A approval of [1-13C]pyruvate as an imaging agent, and certain
ecific obstacles will have to be addressed in designing them. In
dition to requiring novel imaging hardware, acquisition methods,
d analysis, HP 13C MRI carries the added challenge of requiring
e administration of a short-lived, locally produced imaging probe,
e production of which requires onsite personnel with expertise in
oducing HP agents, monitoring their quality, and assuring patient
fety and regulatory compliance. The ability to produce uniformly
gh-quality HP imaging agents across multiple centers is therefore a
ucial step in moving to multicenter clinical trials and eventual
inical practice. Once again, some lessons can be learned from recent
ultisite tests of investigational PET probes, which share many of
ese requirements.134,135 The foremost requirement is that of
lidated, uniform standards for probe production that will support
uivalent probe quality across all sites involved participating in
ulticenter trials. This allows operation under a common regulatory
amework—for example, an NCI-held IND136 for multicenter
inical trials—and assures patient safety and consistency of the drug
oduct. Standardized, robust image acquisition methods are also
eded, as are methods for testing and qualifying equipment and
rsonnel involved in HPMRI studies to ensure high-quality imaging
ta at all participating sites.
Experience suggests a multistep approach leading to multicenter
ials for novel imaging approaches such as MRI of HP [1-13C]
ruvate119 will be key for obtaining full FDA approval. Early studies
test the potential accuracy and utility of new imaging methods are
ten best done in single-center studies at expert institutions invested
the technology. Early multicenter phase II trials should be small
ough to assure the ability of sites to acquire the imaging data in a
iform and reproducible fashion and should validate the findings
om single-center trials; indications supported by small multicenter
ials can then be carried into larger phase III studies using well-
fined, prospective procedures for image analysis, with study design
d sample size calculations guided by results from smaller multisite
single-site trials. Larger phase II trials should include endpoints for
fety and efficacy—in this case defined as diagnostic accuracy. These
rger studies should also gather information on therapeutic impact
d cost-effectiveness, key data for coverage decisions by the Center
r Medicare and Medicaid Services and other payers.
ducation, Training, and Certification
In addition to regulatory approval, translation to clinical practice
ill require training for staff members who produce HP probes and
rry out HP 13C MR imaging. Imaging physicians will also need to
trained in this new imaging modality: not only how to interpret the
ta it provides but also how to safely and effectively administer HP
aging probes. Experience with other highly specialized imagingethods such as PET and breastMRI137,138 suggests that requirements
r physician training and certification will be important in assuring
iform diagnostic quality across all sites of practice. Finally, even after
inical practice implementation, ongoing clinical research will be
itical for sustaining and optimizing clinical use.
ecommendations for Future Research
nce the publication of the first NIH white paper on hyperpolarized
C MRI in 2011, numerous preclinical studies have demonstrated
is technology's unique metabolic imaging capabilities in the context
cancer. There have now been over 200 HP 13C MRI human
udies performed to date worldwide at 7 different medical centers,
d over 5 more sites plan to initiate patient studies within the next 6
onths. All of these studies have shown that HP 13C pyruvate MRI is
fe and also effective in detecting key metabolic conversions in
tients with a variety of diseases and even in normal volunteers. It is
portant to recognize that demonstrating the clinical safety and
asibility of HP MRI technology is not enough to ensure its
idespread clinical implementation. If the latter is to be achieved, it
ill be because future trials are able to successfully establish its clinical
ility. In addition, widespread clinical implementation also implies
gulatory approval and reimbursement approvals around the world.
ommercialization of HP [1-13C]pyruvate MRI will require a
mprehensive regulatory and sponsorship strategy that will also
pend on the potential clinical utility. We have developed a number
recommendations with this ultimate goal in mind.
First, it is necessary to continue refining the protocols, new HP
ents, and investigative targets of ongoing preclinical studies in a
anslational direction with refined pharmacy methods for reliable,
wer-cost production of sterile HP solutions. Also, it is valuable to
rify that metabolic measurements in animal models of cancer and
her disease states correspond to those performed in human disease,
d to incorporate these measurements into disease hypothesis testing
d development of new hyperpolarized agents. Improved quantita-
e analysis of metabolite signals and enzymatic rate kinetics obtained
om HP [1-13C] pyruvate will be a critical aspect of this. It is also
perative to identify the metabolic network(s) associated with the
etabolism of specific hyperpolarized agents in order to select the
propriate agent for the study of specific disease conditions and
erapies, and to appropriately guard against incorrectly associating
parent metabolic changes with the wrong cause. Additionally, there
a need for more studies which focus on determining the origins of
riability in therapeutic response through separate HP measures of
take and metabolism, and to use these HP probes to identify and
tter understand therapeutic response and nonresponders at earlier
e points.
Further efforts to develop improved imaging pulse sequences and
F coils for imaging different organs, agents, and disease states will be
itical for increased quality, information content, and applicability.
ew RF hardware should enable body-coil transmit and multichan-
l (32 at least) reception for all parts of the body with both 13C and
frequency excitation and reception. Analysis methods for the
liable calculation of enzymatic rate constants, such as kPL for the
H catalyzed conversion of pyruvate to lactate and kPB for pyruvate
bicarbonate, need to be refined and tested in patient and volunteer
udies at multiple sites. In the context of cancer more specifically,
other vital avenue for future studies will be the development of new
P agents capable of probing the ancillary and often-unexpected
etabolic changes leading to increased cancer cell survival after
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12 Clinical Translation of Hyperpolarized Carbon-13 MRI Kurhanewicz et al. Neoplasia Vol. 21, No. 1, 2019erapy. Specialized MR pulse sequences for the new agents will be
quired and 1H detected-13C spectroscopy techniques should be
veloped and investigated for increased sensitivity with the added
vantage that spatial information can be encoded at the 1H
equency.
There are also a number of needs to be addressed at an institutional
vel. First and foremost, the mechanism(s) for multisite clinical trials
ust be established—both through the identification of sites that
ssess the necessary equipment and by developing the appropriate
vestigative protocols. In order to support these efforts, it is
portant to promote the development of pedagogical resources for
al-time metabolic imaging, perhaps through the establishment of
w pre- and postdoctoral training programs focused on developing
levant techniques.
Finally, widespread clinical translation will not be possible without
e continued development of robust collaborations among basic
ience investigators, clinical oncologists, and those with expertise in
inical study design. This collaborative work must be bolstered by
rong partnerships between academia, funding agencies, and
dustry.
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